Changes in protein function underlie the disease spectrum in patients with CHIP mutations

Area of Science:

• Neurogenetics
• Molecular Biology
• Biochemistry

Background:

• Monogenetic disorders causing cerebellar ataxia present with gait defects and cerebellar atrophy.
• Spinocerebellar ataxia autosomal recessive 16 (SCAR16) arises from mutations in STUB1, encoding the CHIP protein, leading to a spectrum of neurological and endocrine symptoms.
• Understanding the link between STUB1 mutations, CHIP protein function, and SCAR16 clinical variability is crucial for effective treatment.

Purpose of the Study:

• To investigate the relationship between SCAR16 patient phenotypes and the biophysical, biochemical, and functional alterations of mutated CHIP protein.
• To identify specific biochemical properties of CHIP that correlate with distinct clinical manifestations of SCAR16.
• To explore the potential of targeting CHIP activity for patient-specific SCAR16 treatment strategies.

Main Methods:

• Analysis of clinical phenotypes in SCAR16 patients.
• Biophysical and biochemical characterization of mutated CHIP protein variants.
• Statistical modeling to correlate biochemical properties with clinical severity and specific symptoms.

Main Results:

• Ataxia severity did not correlate with age of onset, but cognitive dysfunction, increased tendon reflex, and ancestry predicted 54% of ataxia severity variation.
• Domain-specific relationships were identified between CHIP biochemical changes and clinical phenotypes.
• Specific biochemical activities of CHIP were found to associate selectively with increased tendon reflex or cognitive dysfunction, implicating CHIP-HSC70 dynamics in SCAR16 pathogenesis.

Conclusions:

• Biochemical alterations in the CHIP protein are directly linked to the clinical spectrum of SCAR16.
• Targeting mutant CHIP activity may offer a therapeutic avenue for SCAR16, potentially leading to patient-specific treatment approaches.
• Further research into CHIP-HSC70 dynamics can elucidate SCAR16 mechanisms and guide drug development.